Fexuprazan
Erosive Esophagitis (GERD)
Phase 3NDA Submitted in Japan
Key Facts
About Nxera Pharma
Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.
View full company profileTherapeutic Areas
Other Erosive Esophagitis (GERD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fexuprazan (Fexuclue) | KYORIN Pharmaceutical | Filed |